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INTRODUCTION
The burden of mood disorders upon women in the United States is substantial, with a
lifetime prevalence rate of approximately 25% in adult women compared to 17% in adult
men [1]. This gender difference is further magnified when taking into consideration the
exclusivity of menstrually related mood disorders (MRMDs) to women only. Menstrually
related mood disorders represent a constellation of clinically significant affective,
behavioral, and physical symptoms, along with functional impairment, occurring in the late
luteal phase of the menstrual cycle and remitting shortly after the onset of menses [2, 3].
Among premenopausal women, approximately 30% experience some form of a MRMD,
including the 8% of women who suffer from premenstrual dysphoric disorder (PMDD), the
most severe MRMD [4–6]. The disability adjusted life years lost due to a MRMD is within
the same magnitude as other affective and anxiety disorders, such as major depressive
disorder (MDD) and posttraumatic stress disorder [5, 7], and is associated with a significant
risk of attempted suicide [8].
Despite more than 65 years of research investigating MRMDs, underlying
pathophysiological mechanisms remain elusive. There is recent evidence that psychosocial
history may provide the context for distinct pathophysiological phenotypes in MRMDs. For
example, women with both a MRMD and a history of sexual or physical abuse show a
unique thyroid axis and adrenergic profile relative to women with a MRMD, but no history
of abuse [9–11].
A history of depression provides another context of vulnerability that may be of particular
relevance to MRMD. A history of depression and other affective disorders has been reported
in 30–70% of women with a MRMD [8, 12–14]. Not only are women with a MRMD more
likely than non-MRMD women to have experienced a prior episode of depression [13, 15],
but a MRMD also predicts the development of major depressive disorder (MDD) [16–18].
The comorbid relationship between MDD and MRMDs has fueled studies investigating the
nosology of the two disorders. While MDD and MRMDs do share genetic and
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environmental risk factors to a modest degree [19], it has been argued that MRMDs are a
distinct entity when compared to other mood disorders in terms of cognitive factors,
physiological biomarkers, and treatment outcomes [14, 20].
Examination of stress responsive pathways may shed light on unique versus shared stress
phenotypes in MRMD compared with other mood disorders, since both MRMDs and other
mood disorders are associated with increased daily stress [21–24] and are either triggered or
exacerbated by stressful life events [19, 25–27]. Although studies examining stress
responses in women with a MRMD have been scant, and results mixed [e.g. 28], the
majority of evidence points toward hypo-responsiveness to challenge in both the
hypothalamic pituitary adrenal (HPA) axis [22, 28–33] and the sympathetic nervous system
(SNS) [21, 22, 35] in women with a MRMD relative to women without a MRMD [36].
While hyperactivity of the HPA and SNS stress axes is consistently found in patients with
current melancholic depression [37–47], studies of euthymic patients with a history of
depression have produced conflicting results, showing hyperactivity [35, 48–53],
hypoactivity [54–56] or no differences [54, 56] relative to never depressed controls in
measures reflecting SNS or HPA axes. Stress response dysregulation in those with a history
of depression, as found in the majority of previous studies, may be clinically relevant, since
a recent study in remitted MDD patients reported HPA-axis dysregulation in response to a
mild stressor may predict the development of future depressive symptoms [57].
Few studies have directly compared MRMD women with women who have suffered from
other mood disorders for stress reactivity phenotypes. The results of such investigations may
be relevant to understanding not only the pathophysiology of mood disorders in general, but
particularly that of MRMDs. The primary aim of the present study was to compare women
with MRMD to non-MRMD women, approximately half of whom had a history of
depression, and to investigate whether the hypoactive responses to stressors previously
reported in women with a MRMD reflect a unique phenotype of MRMDs or could more
parsimoniously be explained by a history of depression in this population. A secondary,
exploratory aim was to investigate the relationship of stress reactivity to premenstrual
symptomatology in order to examine any potential pathophysiological relevance of stress
reactivity to mood disorders.
METHODS
Participants
The sample of 126 women (19–51 years of age) who comprise this report were recruited via
newspaper, radio, or posted advertisements targeting either women with severe premenstrual
symptoms or women without premenstrual symptoms. The final sample of participants was
composed of four groups: 1) Women with a MRMD without a history of depression (n =
37); 2) Women with a MRMD plus a history of depression (n = 26); 3) Women without a
MRMD and without or depression (n = 43); and 4) Women without a MRMD but with a
history of depression (n = 20).
Participants with a current Axis I psychiatric disorder were excluded (based on interview,
see below), but referred for treatment. Women who were pregnant or breastfeeding, had
irregular menstrual cycles, taking prescription medication (including oral contraceptives and
psychotropics), had a cardiovascular disorder, a current chronic or acute pain condition, an
endocrine disorder (including diabetes or thyroid disorder), or other chronic medical illness,
were also excluded from the final sample. A diagnosis of a history of depression was based
on a structured clinical interview (see below). The never depressed groups were free of any
lifetime depressive illness, including minor depression, dysthymia and adjustment disorder
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with depressed mood. The protocol was approved by the institution’s Institutional Review
Board, and all participants provided informed, written consent. Participants received $100
compensation.
Procedures
Screening and Enrollment—During the enrollment session, informed consent was
obtained, as was a series of stethoscopic blood pressures and a medical history. Participants
were instructed on the Daily Record of Severity of Problems (DRSP) form [58], which they
were asked to complete daily for 2–3 consecutive menstrual cycles in order to confirm the
diagnosis of MRMD. Upon completion of the DRSP ratings, a comprehensive psychiatric
history was obtained.
Confirmation of MRMD Diagnosis—MRMD and non-MRMD status was confirmed
prospectively using the DRSP [58]. The DRSP forms were mailed back weekly in order to
discourage retrospective reporting. The DRSP consists of 24 items and allows for the
quantification of the severity of physical, emotional and behavioral symptoms of MRMD as
well as functional impairment using a 6-point scale (1 = absent, 2 = minimal, 3 = mild, 4 =
moderate, 5 = severe and 6 = extreme). A diagnosis of MRMD was based on the following
criteria: (1) at least a 30% decrease in emotional symptom severity from the seven luteal
phase days preceding menses compared with follicular phase days 4–10; (2) a rating of
emotional symptoms as moderate, severe or extreme on at least two of the seven
premenstrual days; (3) remission of symptoms shortly after the onset of menses followed by
a clear symptom free period (≥ 6 consecutive days) during the early-to-mid follicular phase
and (4) criteria 1–3 met in at least two menstrual cycles [58, 59]. Since we did not require
the arbitrary 5 or more different symptoms during the luteal phase as required by the DSM-
IV for the diagnosis of premenstrual dysphoric disorder (PMDD), we describe our sample as
women with a menstrual mood disorder (MRMD). However, 53 (84%) of the women in this
report did, in fact, display 5 or more symptoms premenstrually that met severity and
remission criteria above (criteria 2 and 3) and would therefore meet DSM-IV criteria for
PMDD.
Women without a MRMD met the following criteria: (1) no more than minimal emotional
symptoms occurring on fewer than three days during the premenstrual week; (2) less than a
30% decrease in emotional symptom severity from the luteal to the follicular phase; and (3)
these criteria met in at least two menstrual cycles.
A total of 232 women were prospectively evaluated for MRMD, with 78 (33%) meeting
prospective criteria consistent with other reports [21]. A total of 85 entered as non-MRMD
controls, with 79 (93%) meeting prospective control criteria. Following the prospective
diagnostic phase, 14 MRMD women did not enter into the experimental phase of the study
(8 lost to follow-up, 5 declined, and 1 was withdrawn) and 16 non-MRMD women did not
enter into the experimental phase of the study (9 lost to follow-up, 1 declined, and 6 were
not tested due to laboratory relocation at that time). One additional woman with a MRMD
was enrolled in the study, but was not included in the analyses because no SNS data was
collected due to equipment error. Consequently 63 women with MRMD (26 with a history
of depression) and 63 non-MRMD women (20 with a history of depression) comprise the
sample for this report.
Diagnosis of Psychiatric Disorders—The MINI Structured Psychiatric Interview [60]
was used to evaluate all women for current and past Axis I psychiatric disorders. All
diagnoses were based on a consensus diagnostic session with a clinical psychologist. Since
lifetime histories of mood disorders are prevalent in women with a MRMD [13, 15], one
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year in full remission was required for mood disorders, while for other Axis I disorders three
years in remission was required.
Test Session—All laboratory sessions took place during the luteal phase of the menstrual
cycle, 5–12 days after home urine ovulation testing indicated the luteinizing hormone surge
that indicates ovulation (corresponding to days 18–25 of an idealized 28 day cycle). The
luteal (symptomatic) phase was the only phase studied since there is little consistent
evidence that menstrual cycle phase influences blood pressure (BP) or heart rate (HR)
reactivity in healthy controls [61, 62] or BP, HR, and neuroendocrine differences between
MRMD and non-MRMD groups at rest or during stress [21, 22, 32, 34].
All laboratory testing began between the hours of 7:00 am and 9:30 am. The laboratory visit
lasted approximately three hours and thirty minutes and followed a fixed sequence.
Although the entire testing sequence is reported here, we focus solely on the results of the
stress testing portion of the protocol in the present report.
The order of testing was as follows: 1) Instrumentation for BP monitoring (Suntech 4240
Exercise BP monitor) and stethoscopic BP assessments to ensure reliable cuff placement and
microphone position; 2) IV setup and recovery; 3) Baseline 1 Rest; 4) Beck Depression
Inventory-II (BDI-II) and Spielberger State Anxiety Inventory (SAI); 5) Pain Testing; 6)
Recovery; 7) Baseline 2 Rest; 8) Trier Social Stress Test (TSST).
Intravenous Blood Draw Setup: A research nurse inserted a butterfly needle into a forearm
vein. A non-heparinized, multi-stop-cock system was employed, to allow the nurse to draw
blood samples without the added stress involved in multiple venipunctures. Once the needle
was in place, a curtain was drawn to prevent the participant from viewing blood sampling. A
15 minute recovery period followed the intravenous blood draw setup.
Baseline 1 Rest: Participants rested quietly for 10 minutes in order to serve as the baseline
for pain testing. Depression and state anxiety were measured at the end of this rest period
using the BDI-II and SAI.
Pain Testing: Participants were exposed to two pain tests: the submaximal effort tourniquet
procedure and the hand cold pressor. Results and details on the pain testing procedure are
reported elsewhere [63].
Recovery: A five minute recovery period followed each pain task.
Baseline 2 Rest: Following the recovery period, quiet rest ensued for an additional 10
minutes, serving as a baseline from which to calculate SNS reactivity. Blood pressure and
HR measures were taken at minutes 1, 3, 6, and 9 and averaged. Blood was sampled at
minute 10 for baseline levels of norepinephrine (NE).
The Trier Social Stress Test (TSST): A modified version of the TSST [64] was employed
(modified to include serial addition as opposed to serial subtraction). The TSST is a stress
test which reliably induces large and consistent cardiovascular responses [64–66]. The TSST
involves four components: 1) Pre-Task Instructions (5 minute) during which time
participants are told that the first task entails giving a speech that will serve as an interview
for their ideal job and are then introduced to the ‘selection committee’ who will later listen
to their job talk. Participants are also given the instructions for the mental arithmetic task. 2)
Speech Preparation Period (5 minute): Participants were told that they should imagine that
they are applying for their ideal job and were then left alone for 5 minutes to prepare their
talk describing why they would be the ideal candidate for the position; 3) Job Speech (5
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minute): Immediately following the preparation period, the selection committee returned to
the testing room and asked the participant to deliver her talk describing to the committee
why she would be the perfect applicant for the position. If the participant finished before 5
minutes, the committee responded in a standardized way, with prepared questions to ensure
that the participant spoke for the entire period; and 4) Paced Auditory Serial Addition Test
(PASAT; [67]) (8.5 minutes): Involves the tape recorded presentation of numbers from 1 –
9. Participants are to add each number presented on the tape to the immediately preceding
number and to state the answer out loud to the committee. There are four series of numbers,
with progressively shorter inter-digit intervals (2.4, 2.0, 1.6, and 1.2 seconds). The
experimenter remained in the room to monitor performance.
Task Assessments: Task assessment questionnaires were administered after the cessation of
the TSST. Using a visual analog scale, the participants rated: 1) how difficult they found the
task; 2) how tense they were during the task; 3) how well they were able to concentrate
during the task; and 4) how much effort they put into the task.
Cardiovascular Sampling During the TSST: All measurements took place while
participants were in a comfortable seated position. Blood pressure and HR measures were
taken at minutes 1, 3, and 5 of the Speech Preparation Period, minutes 1, 3, and 5 of the Job
Speech, and minutes 2, 4, 6, and 8 of Serial Addition and averaged to constitute task levels.
Norepinephrine was sampled at the end of minute 2 of Speech and minute 2 of Serial
Addition since catecholamines peak within the first minutes of stress and have a short half-
life (3 min) [68].
Measurements
Physiologic recording procedures—The Suntech Exercise BP monitor, Model 4240
(SunTech Medical Instruments, Inc., Raleigh, NC) provided automated measurement of
systolic BP, diastolic BP and HR during the sessions. Prior to initiating the Baseline 1 Rest
period, five standard stethoscopic blood pressures were taken simultaneously with the
automated pressures in order to ensure correct microphone placement and cuff positioning.
Impedance cardiography was used to permit non-invasive monitoring of cardiac
performance [69]. A custom-designed impedance cardiograph (HIC-100, Bioimpedance
Technology Inc., Model 100, Chapel Hill, NC, USA) was used in conjunction with a
tetrapolar band electrode configuration to record impedance dZ/dt and Z0 signals.
Impedance and electrocardiogram signals were processed on-line by specialized computer
software (BIT, Chapel Hill, NC) with subsequent manual editing to improve accuracy. For
each minute of interest, a 30 s continuous sample of waveforms (obtained concurrently with
BP) was processed to generate an ensemble-averaged cardiac cycle, from which stroke
volume (SV) was determined by means of the Kubicek et al. [70] equation and HR was
determined by the mean interbeat interval. Cardiac output (CO) and total peripheral
resistance (TPR) for these same minutes were then calculated using standard formula [69].
Since we found that, in those with no history of depression, women with a MRMD had a
greater BMI than women without a MRMD (see results), SV, CO and TPR were adjusted for
body surface area (BSA), yielding stroke index (SVI), cardiac index (CI), and total
peripheral resistance index (TPRI). BSA was calculated using the following formula: BSA
(m2) = W(kg)0.425 × H(cm)0.725 × .007184.
Norepinephrine concentrations—Plasma levels of NE were determined using the high-
pressure liquid chromatography with electrochemical detection (HPLC-ECD) technique.
The lower limit of quantification is 2.5 pg/ml, and the intra- and inter-day coefficients of
variation are less than 10%.
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Group differences in demographic factors, state anxiety and depression scores, as well as
baseline SNS factors were examined using a 2 (MRMD: yes vs. no) × 2 (History of
Depression: yes vs. no) ANOVA for continuous variables and chi square analyses for
dichotomous variables as appropriate. For women with histories of depression, MRMD and
non-MRMD groups were compared on months since last major depressive episode with a
one way ANOVA. Where significant interactions emerged, simple effects analyses
performed separately in prior depression or MRMD groups were conducted to explore the
source of the interaction.
Daily Symptom Ratings
For each of the 24 DRSP symptoms, a follicular (days 4 through 10) and luteal (days −7
through −1 before menses) phase average was calculated for cycle one. Average
premenstrual symptom severity from the first menstrual cycle only was analyzed in order to
avoid the confounding effect that repeated symptom monitoring over several months may
have on symptoms [71]. Next, each symptom was placed into one of five core symptom
categories [58]: 1) Somatic (fatigue, breast tenderness, breast swelling or bloating, headache,
joint or muscle pain); 2). Depression: (depressed, hopeless, worthless or guilty, slept more,
trouble sleeping, overwhelmed); 3) Anger/Irritability: (anger or irritability, conflict); 4)
Anxiety: (anxiety); and 5) Impairment: (less productivity or efficiency, interference with
hobbies or social activities, interference with relationships), and averaged to yield one total
follicular and luteal score for each of the five core categories.
Women were assessed for differences in the five core symptom categories using a 2
(MRMD) × 2 (History of Depression) × 2 (Menstrual Cycle Phase) repeated measures
ANOVA with Menstrual Cycle Phase as the repeated factor. Where significant interactions
emerged, simple effects analyses conducted separately in prior depression or MRMD groups
were conducted to explore the source of the interaction.
Sympathetic Nervous System (SNS) Stress Reactivity
Group differences in baseline measures were analyzed using a 2 (MRMD) × 2 (History of
Depression) ANOVA. Next, cardiovascular and NE stress responsivity were examined by
calculating delta scores (Stress task – Baseline) and performing a 2 (MRMD) × 2 (History of
Depression) × 2 (Stress Task: Speech vs. Math) repeated measures ANOVA with stress task
as the repeated factor.
Sympathetic Nervous System (SNS) Stress Reactivity and Premenstrual Symptom Severity
Ratings
In order to explore the role of sympathetic stress reactivity in premenstrual symptom
severity, exploratory analyses examining the relationship between SNS stress reactivity and
luteal phase symptom severity ratings for the five core symptom categories were conducted
using Pearson’s correlational analyses. In order to reduce Type I error rates, and because of
the relatively small cells sizes, we created a mean reactivity score for each dependent
measure (averaging speech and math reactivity), conducted these analyses in the entire
sample of women, and restricted these analyses to SNS measures that were found to differ
by MRMD status or history of depression (see Results). Consequently, we examined the
relationship between daily symptom severity ratings and HR, DBP, NE, and CI reactivity to
stress.
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Subjective Response to Stress
The participants’ experiences of each stress task (difficulty, tension, inability to concentrate,
effort) as measured by the task assessment questionnaire was analyzed by MRMD and
history of depression status using a 2 (MRMD) × 2 (History of Depression) ANOVA. The
analyses were performed separately for the speech and math tasks and for each of the 4
items on the task assessment. Higher scores indicate greater difficulty, tension, inability to
concentrate, and effort.
RESULTS
Demographics and Baseline Measures
As summarized in Table 1, no group differences emerged for age, BMI, or minority race (ps
> .05). Women with a MRMD had higher luteal phase depression (F(1, 122) = 28.0, p < .
001) and state anxiety ratings (F(1, 122) = 7.9, p < .01) than women without a MRMD. All
but one participant in the groups with a history of depression had a history of major
depressive disorder; the other woman had a history of dysthymia. Women with and without
a MRMD did not differ in months in remission from their most recent depressive episode
(all ps >.05). Women with histories of depression were more likely to have a history of
anxiety disorders (χ2 (1) = 15.2, p < .001), substance abuse (χ2 (1) = 13.3, p < .01), and
suicidality (χ2 (1) = 21.1, p < .001) than women without a history of depression.
There were no significant group differences involving resting cardiovascular measures
(Table 2).
Daily Symptom Ratings
As expected, MRMD × Menstrual Cycle Phase interactions were present for all core
symptom categories assessed via the DRSP [58] [somatic: F(1, 122) = 55.1, p < .001,
depression: F(1, 122) = 72.5, p < .001, anger/irritability: F(1, 122) = 135.8, p < .001,
anxiety: F(1, 122) = 69.72, p < .001, and impairment: F(1, 122) = 62.3, p < .001], reflecting
both a significant phase effect on symptoms in MRMD women only (ps < .001) and the
greater MRMD-related differences for all symptom categories in the luteal phase that were
not evident in the follicular phase (ps < .001) (Figure 1). Additionally, a History of
Depression × Menstrual Cycle Phase interaction emerged for impairment symptoms (F(1,
122) = 5.5, p < .05). Simple effects analyses revealed that women with a history of
depression reported greater impairment than women with no history of depression in the
luteal phase (t(124) = 2.3, p < .05).
Sympathetic Nervous System (SNS) Stress Reactivity
Both the speech and math task induced significant increases in HR, SBP, DBP, CI reactivity
and decreases in TPRI reactivity (Fs(1, 115–119) = 19.4 – 503.6, ps <.001). Stroke volume
index did not change significantly as a result of the stress tasks. Despite the absence of
diagnosis-related differences in any cardiovascular and NE measures at baseline rest (Table
2), women with a MRMD had blunted HR (F(1, 118) = 8.7, p < .01) and CI (F(1, 116) = 9.1,
p < .01) reactivity to stress relative to women without a MRMD, regardless of depression
histories (Figures 2 and 3). There was also a MRMD × History of Depression interaction for
NE stress reactivity (F(1, 100) = 4.1, p < .05) and a trend for DBP stress reactivity (F(1,
115) = 3.0, p = .09). Women with a MRMD showed blunted DBP (F(1, 75) = 11.37, p < .01)
and NE (F(1, 65) = 9.59, p < .01) responses to stress relative to women with no MRMD, but
only in women with no history of depression (Figures 4 and 5). There were no significant
effects involving SBP, SVI or TPRI stress reactivity (Table 2).
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Sympathetic Nervous System (SNS) Stress Reactivity in Relation to Daily Symptom
Ratings
In the sample as a whole, blunted stress reactivity predicted greater luteal phase symptom
severity. Specifically, blunted HR and CI reactivity to stress predicted greater premenstrual
depression (rs = −0.20 and −0.23, respectively, ps < .05), anger/irritability (rs = −0.19 and
−0.21, respectively, ps < .05), and anxiety (rs = −0.25 and −0.24, respectively, ps < .05).
There were no statistically significant relationships involving DBP or NE reactivity and
premenstrual symptomatology.
Subjective Responses to Stress
Women with a MRMD, regardless of depression history, reported greater difficulty during
speech stress (F(1, 117) = 8.3, p < .01) and inability to concentrate during math stress (F(1,
118) = 8.7, p < .01) than women without a MRMD. Women with a history of depression,
regardless of MRMD diagnosis, reported greater difficulty during math stress (F(1, 118) =
3.9, p = .05) than women without a history of depression. A MRMD × History of
Depression interaction emerged for tension during the speech task (F(1, 117) = 4.8, p < .05),
since only in women with a history of depression did women with a MRMD report greater
tension (F(1, 117) = 12.4, p <.01) than women without a MRMD.
No statistically significant group differences in subjective effort ratings were found for the
speech or math stress tasks.
DISCUSSION
The chief findings of this investigation were: 1) women with a MRMD showed blunted
myocardial (HR and CI) reactivity to mental stress compared to non-MRMD women,
irrespective of histories of depression; 2) women with a MRMD showed blunted NE and
DBP stress reactivity relative to women with no MRMD, but only when no history of
depression was present; 3) blunted HR and CI stress reactivity predicted greater
premenstrual symptom severity. These results suggest that MRMDs are associated with
blunted myocardial reactivity to mental stress, while for NE and DBP, this hypo-reactivity in
MRMD women is seen only in women with no history of depression. Nonetheless, these
results support the contention that a blunted SNS reactivity profile represents a unique
phenotype of MRMDs that is not explained by a history of depression. Moreover, the
preliminary results suggest that the phenotypic profile of blunted myocardial stress reactivity
may be pathologically relevant since it predicts heightened luteal phase affective symptom
severity.
Blunted cardiovascular reactivity to stress in women with MRMDs has been previously
documented, though most studies did not control for depression histories [21, 22]. Blunted
myocardial stress reactivity in MRMDs would be consistent with alterations in the
myocardial β1-adrenergic receptors (β-AR), which mediate both inotropic and chronotropic
heart activity, and which have been previously implicated in MRMDs as suggested by
several lines of evidence. First, estrogen and progesterone, which are pathophysiologically
relevant in MRMDs [72], modulate the activity and expression of β-ARs in animal models
[73–75]. In humans, the density of lymphocytic β2-ARs vary with menstrual cycle phase
[76]. Second, the clinical relevance of β-ARs to MRMDs was suggested by the findings of
Gurguis et al. [77] who observed diagnostic differences in β2-AR density in MRMD relative
to non-MRMD women, and that β2-AR binding predicted premenstrual symptom severity.
Extending this line of evidence for the pathophysiological relevance of blunted myocardial
reactivity in MRMD was our correlational analyses, albeit conducted in the full sample of
women, showing that lower HR and CI stress reactivity predicted greater premenstrual
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depression, anxiety, and anger/irritability. Thus, the pattern of stress reactivity that
differentiated MRMD from non-MRMD women was predictive of clinical symptomatology.
This is consistent with the results of a recent longitudinal study in over 1,000 participants
that showed lower HR reactivity to mental stress predicted greater depression severity scores
over five years, even after controlling for baseline characteristics, medication use, and other
potential confounds [78]. These investigators speculated that alterations in β-AR receptor
mechanisms and/or vagal tone may mediate the link between blunted myocardial stress
reactivity and the development of depressive illness. If this is the case, this could contribute
to the association between a MRMD and the incident development of a major depressive
disorder [16–18]. Although preliminary, replication of our findings for blunted myocardial
stress reactivity predicting premenstrual symptoms could implicate SNS hypo-reactivity as a
physiological mechanism mediating the link between MRMDs and the increased risk for the
development of future depressive episodes [16–18].
Although we did not obtain statistical evidence that a history of depression, per se, is
associated with blunted stress reactivity, that is not to say that such a history is not of
relevance to the stress reactivity phenotype of women with a MRMD. Specifically, only in
women who had no other depression history did we see blunted NE and DBP stress
reactivity in MRMD women compared to women without a MRMD. Thus, a history of
depression served to mask the generally hypoactive stress reactivity profile that we and
others have previously reported in women with a MRMD. Examination of the mean DBP
and NE reactivity data (Figures 4 and 5), suggests that this masking came about because of
the generally blunted DBP and NE stress reactivity in non-MRMD women with prior
depression (relative to never depressed non-MRMD women). Consequently, in women with
a depression history, DBP and NE reactivity were roughly equivalent between MRMD and
non-MRMD women. Nonetheless, these results contribute to the growing appreciation for
the contextual role of psychiatric history in stress reactivity. For example, the presence or
absence of a history of sexual abuse has been shown to differentially modify reactivity to
challenge in women with a MRMD [10, 79]. Consequently, the lack of appreciation for the
influence that historical context may have on stress reactivity may contribute to
discrepancies in the literature on stress reactivity in women with a MRMD and other mood
disorders.
The finding that a MRMD is associated with blunted SNS stress reactivity is not inconsistent
with conceptualizations of MRMDs as a chronic disorder, despite time limited
symptomatology. The cyclic recurrence of symptoms and a cyclic pathophysiologic trigger
(unknown at present) persists for decades during a woman’s reproductive years. While
cardiovascular responses to stress are adaptive in the short-term, long-term activation of
such responses due to repeated or chronic stress may lead to persistent dysregulation in
stress responsive systems. In humans, the price of repeated biological adaptations to stress
has been termed allostatic load, referring to the long-term effect of physiologic responses to
stress [80]. Allostatic load, or dysregulation in stress responsive systems, may manifest in a
variety of ways, including repeated elevations of neurohormonal stress mediators (e.g.,
norepinephrine) over long periods, as a failure to adapt to a stressor, as a failure to shut off
the normal stress response, or as an inadequate response to stress [80, 81]. It has been
suggested that such hypoactivation of stress responsive systems may result from a wearing
out or exhaustion of the system due to longterm stress exposure and allostatic load [80].
Thus, chronic mood disorders may increase allostatic load in stress-responsive pathways,
leading to long-term blunted sympathetic stress reactivity to even relatively mild stressors in
the future. The clinical relevance of increased allostatic load comes from substantial
evidence indicating that it is associated with increased risk for both cardiovascular disease
and depression [see 82].
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Lastly, both MRMD women and women with depression histories reported greater negative
subjective responses to stress relative to their non-MRMD and never depressed counterparts.
These results are unlikely to explain the stress reactivity differences since both MRMD
women and women with a depression history endorsed greater difficulty with the tasks, and
only those with both a depression history and MRMD reported greater tension (which would
be expected to be associated with greater, and not lesser, stress reactivity). However, these
results are consistent with a recent study showing heightened negative affect in response to
stress in women with a history of depression [54]. If a history of depression increases the
propensity to respond to stressors with greater negative affect or cognitive schemas, this
could contribute to our findings for greater premenstrual functional impairment in women
with a depression history relative to never depressed women. Since negative affect has been
shown to predict the development of a future depressive episode in never-depressed
individuals [83] as well as in those with a history of depression [84], altered affective
regulation during stress may contribute to the greater likelihood of women with a MRMD
experiencing future major depressive episodes [16–18]. If these findings are confirmed in
longitudinal research, these results would suggest a potential therapeutic target for
behavioral intervention that may decrease risk for stress-induced affective dysregulation in
women with a history of depression and in women with a MRMD.
While this study has many notable strengths, including the use of strict diagnostic criteria
based on a structured clinical interview and daily prospective ratings to establish the MRMD
diagnoses, as well as a comprehensive assessment of stress-relevant SNS biomarkers, it is
not without its limitations. First, although cycle phase was controlled for, the absence of
follicular phase testing limits any interpretation about diagnostic-related differences in stress
reactivity as a function of cycle phase. However, our prior research found blunted
cardiovascular reactivity in MRMD women relative to non-MRMD women in both the
follicular and luteal phases [21, 22]. A further limitation may be the possibility of a
carryover effect from the pain testing [reported in 63] to the stress testing for measures of
SNS stress reactivity. However, prior research from this laboratory in healthy non-MRMD
and never depressed individuals did counterbalance the order of pain testing and mental
stress testing using identical pain and stress tests employed in the present study, and found
no evidence that the order of events influenced responses to either the pain test or the mental
stress test [85]. Furthermore, by including a second baseline following pain testing it is
unlikely that a carryover effect played a role in the results of the present study.
In conclusion, the present study indicates that women with a MRMD exhibit
hypomyocardial reactivity to stress compared to women without a MRMD and that this
blunted stress reactivity phenotype is predictive of greater premenstrual symptom severity.
Although MRMD-related differences in DBP and NE stress reactivity were only statistically
evident in women with no history of depression, this effect largely resulted from the
generally blunted DBP and NE stress reactivity in the non-MRMD women with a history of
depression. These findings underscore the relevance of psychiatric history to stress reactivity
and suggest a potential mechanism (blunted stress reactivity) by which MRMD may
increase the risk for the development of MDD [16–18]. Longitudinal studies designed to
assess the ability of SNS hypo-reactivity to stress and heightened negative affect in response
to stress to predict premenstrual symptoms as well as the incidence of major depressive
disorder in women with a MRMD are indicated and would inform future intervention
studies.
Acknowledgments
This research was supported by NIH grants RO1-MH051246 and CTRC grant CTSA UL1RR025747.
Klatzkin et al. Page 10














1. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H. Twelve-month and lifetime
prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J
Methods Psychiatr Res. 2012; 21:169–184. [PubMed: 22865617]
2. Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for Premenstrual Dysphoric Disorder:
secondary analyses of relevant data sets. Arch Gen Psychiatry. 2012; 69:300–305. [PubMed:
22393222]
3. Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on research and treatment of
premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009; 17:120–137. [PubMed: 19373620]
4. Biggs WS, Demuth RH. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam
Physician. 2011; 84:918–924. [PubMed: 22010771]
5. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden
of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003; 28:1–23.
6. Pearlstein T, Steiner M. Premenstrual dysphoric disorder: burden of illness and treatment update. J
Psychiatry Neurosci. 2008; 33:291–301. [PubMed: 18592027]
7. Freeman EW, Sondheimer SJ. Premenstrual Dysphoric Disorder: recognition and treatment. Prim
Care Companion J Clin Psychiatry. 2003; 5:30–39. [PubMed: 15156244]
8. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual
dysphoric disorder in the community. Psychol Med. 2002; 32:119–132. [PubMed: 11883723]
9. Bunevicius A, Leserman J, Girdler SS. Hypothalamic-pituitary-thyroid axis function in women with
a menstrually related mood disorder: association with histories of sexual abuse. Psychosom Med.
2012; 74:810–816. [PubMed: 23001392]
10. Bunevicius R, Hinderliter AL, Light KC, Leserman J, Pedersen CA, Girdler SS. Histories of sexual
abuse are associated with differential effects of clonidine on autonomic function in women with
premenstrual dysphoric disorder. Biol Psychol. 2005; 69:281–296. [PubMed: 15925031]
11. Girdler SS, Sherwood A, Hinderliter AL, Leserman J, Costello NL, Straneva PA, Pedersen CA,
Light KC. Biological correlates of abuse in women with premenstrual dysphoric disorder and
healthy controls. Psychosom Med. 2003; 65:849–856. [PubMed: 14508031]
12. Cohen LS, Soares CN, Otto MW, Sweeney BH, Liberman RF, Harlow BL. Prevalence and
predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The
Harvard study of moods and cycles. J Affect Disord. 2002; 70:125–132. [PubMed: 12117624]
13. Pearlstein TB, Frank E, Rivera-Tovar A, Thoft JS, Jacobs E, Mieczkowski TA. Prevalence of axis
I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord. 1990;
20:129–134. [PubMed: 2148327]
14. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders.
J Clin Psychiatry. 1997; 58:19–25. [PubMed: 9427873]
15. Harrison WM, Endicott J, Nee J, Glick H, Rabkin JG. Characteristics of women seeking treatment
for premenstrual syndrome. Psychosomatics. 1989; 30:405–411. [PubMed: 2798733]
16. Hartlage SA, Arduino KE, Gehlert S. Premenstrual dysphoric disorder and risk for major
depressive disorder: a preliminary study. J Clin Psychol. 2001; 57:1571–1578. [PubMed:
11745598]
17. Graze KK, Nee J, Endicott J. Premenstrual depression predicts future major depressive disorder.
Acta Psychiatr Scand. 1990; 81:201–205. [PubMed: 2327284]
18. Roca CA, Schmidt PJ, Rubinow DR. A follow-up study of premenstrual syndrome. J Clin
Psychiatry. 1999; 60:763–766. [PubMed: 10584765]
19. Kendler KS, Karkowski LM, Corey LA, Neale MC. Longitudinal population-based twin study of
retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry.
1998; 155:1234–1240. [PubMed: 9734548]
20. Endicott J, Amsterdam J, Eriksson E, Frank E, Freeman E, Hirschfeld R, Ling F, Parry B,
Pearlstein T, Rosenbaum J, Rubinow D, Schmidt P, Severino S, Steiner M, Stewart DE, Thys-
Jacobs S. Is premenstrual dysphoric disorder a distinct clinical entity? J Womens Health Gend
Based Med. 1999; 8:663–679. [PubMed: 10839653]
Klatzkin et al. Page 11













21. Girdler SS, Pedersen CA, Stern RA, Light KC. Menstrual cycle and premenstrual syndrome:
modifiers of cardiovascular reactivity in women. Health Psychol. 1993; 12:180–192. [PubMed:
8500447]
22. Girdler SS, Pedersen CA, Straneva PA, Leserman J, Stanwyck CL, Benjamin S, Light KC.
Dysregulation of cardiovascular and neuroendocrine responses to stress in premenstrual dysphoric
disorder. Psychiatry Res. 1998; 81:163–178. [PubMed: 9858034]
23. Fontana AM, Badawy S. Perceptual and coping processes across the menstrual cycle: an
investigation in a premenstrual syndrome clinic and a community sample. Behav Med. 1997;
22:152–159. [PubMed: 9138623]
24. Ravindran AV, Griffiths J, Waddell C, Anisman H. Stressful life events and coping styles in
relation to dysthymia and major depressive disorder: variations associated with alleviation of
symptoms following pharmacotherapy. Prog Neuropsychopharmacol Biol Psychiatry. 1995;
19:637–653. [PubMed: 8588062]
25. Kendler KS, Kuhn JW, Prescott CA. Childhood sexual abuse, stressful life events and risk for
major depression in women. Psychol Med. 2004; 34:1475–1482. [PubMed: 15724878]
26. Morris MC, Ciesla JA, Garber J. A prospective study of stress autonomy versus stress sensitization
in adolescents at varied risk for depression. J Abnorm Psychol. 2010; 119:341–354. [PubMed:
20455607]
27. Paddison PL, Gise LH, Lebovits A, Strain JJ, Cirasole DM, Levine JP. Sexual abuse and
premenstrual syndrome: comparison between a lower and higher socioeconomic group.
Psychosomatics. 1990; 31:265–272. [PubMed: 2388980]
28. Lee EE, Nieman LK, Martinez PE, Harsh VL, Rubinow DR, Schmidt PJ. ACTH and cortisol
response to DEX/CRH testing in women with and without premenstrual dysphoria during GNRH
agonist-induced hypogonadism and ovarian steroid replacement. Clin Endocrinol Metab. 2012;
97:1887–1896.
29. Chuong CJ, Coulam CB, Kao PC, Bergstralh EJ, Go VL. Neuropeptide levels in premenstrual
syndrome. Fertil Steril. 1985; 44:760–765. [PubMed: 2934273]
30. Facchinetti F, Fioroni L, Martignoni E, Sances G, Costa A, Genazzani AR. Changes of opioid
modulation of the hypothalamo-pituitary-adrenal axis in patients with severe premenstrual
syndrome. Psychosom Med. 1994; 56:418–422. [PubMed: 7809341]
31. Giannini AJ, Martin DM, Turner CE. Beta-endorphin decline in late luteal phase dysphoric
disorder. Int J Psychiatry Med. 1990; 20:279–284. [PubMed: 2265889]
32. Straneva PA, Maixner W, Light KC, Pedersen CA, Costello NL, Girdler SS. Menstrual cycle, beta-
endorphins, and pain sensitivity in premenstrual dysphoric disorder. Health Psychol. 2002;
21:358–367. [PubMed: 12090678]
33. Bancroft J, Cook A, Davidson D, Bennie J, Goodwin G. Blunting of neuroendocrine responses to
infusion of L-tryptophan in women with perimenstrual mood change. Psychol Med. 1991; 21:305–
312. [PubMed: 1876635]
34. Su TP, Schmidt PJ, Danaceau M, Murphy DL, Rubinow DR. Effect of menstrual cycle phase on
neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in
women with premenstrual syndrome and controls. J Clin Endocrinol Metab. 1997; 82:1220–1228.
[PubMed: 9100599]
35. Klatzkin RR, Lindgren ME, Forneris CA, Girdler SS. Histories of major depression and
premenstrual dysphoric disorder: Evidence for phenotypic differences. Biol Psychol. 2010;
84:235–247. [PubMed: 20138113]
36. Girdler S, Klatzkin R. Biological responses to stress in premenstrual dysphoric disorder: influence
of histories of abuse and depression. Gynaecology Forum. 2006; 11:27–32.
37. Gillespie CF, Nemeroff CB. Hypercortisolemia and depression. Psychosom Med. 2005; 67:S26–
S28. [PubMed: 15953796]
38. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology.
2000; 23:477–501. [PubMed: 11027914]
39. Carney RM, Freedland KE, Veith RC, Cryer PE, Skala JA, Lynch T, Jaffe AS. Major depression,
heart rate, and plasma norepinephrine in patients with coronary heart disease. Biol Psychiatry.
1999; 45:458–463. [PubMed: 10071718]
Klatzkin et al. Page 12













40. Gold PW, Wong ML, Goldstein DS, Gold HK, Ronsaville DS, Esler M, Alesci S, Masood A,
Licinio J, Geracioti TD Jr, Perini G, DeBellis MD, Holmes C, Vgontzas AN, Charney DS,
Chrousos GP, McCann SM, Kling MA. Cardiac implications of increased arterial entry and
reversible 24-h central and peripheral norepinephrine levels in melancholia. Proc Natl Acad Sci
USA. 2005; 102:8303–8308. [PubMed: 15919819]
41. Hamer M, Tanaka G, Okamura H, Tsuda A, Steptoe A. The effects of depressive symptoms on
cardiovascular and catecholamine responses to the induction of depressive mood. Biol Psychol.
2007; 74:20–25. [PubMed: 16860921]
42. Lake CR, Pickar D, Ziegler MG, Lipper S, Slater S, Murphy DL. High plasma norepinephrine
levels in patients with major affective disorder. Am J Psychiatry. 1982; 139:1315–1318. [PubMed:
6289682]
43. Lechin F, van der Dijs B, Orozco B, Lechin ME, Baez S, Lechin AE, Rada I, Acosta E, Arocha L,
Jimenez V, et al. Plasma neurotransmitters, blood pressure, and heart rate during supine-resting,
orthostasis, and moderate exercise conditions in major depressed patients. Biol Psychiatry. 1995;
38:166–173. [PubMed: 7578659]
44. Udupa K, Sathyaprabha TN, Thirthalli J, Kishore KR, Lavekar GS, Raju TR, Gangadhar BN.
Alteration of cardiac autonomic functions in patients with major depression: a study using heart
rate variability measures. J Affect Disord. 2007; 100:137–141. [PubMed: 17113650]
45. Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC, Murburg MM, Ashleigh
EA, Castillo S, Peskind ER, et al. Sympathetic nervous system activity in major depression. Basal
and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry.
1994; 51:411–422. [PubMed: 8179465]
46. Volkers AC, Tulen JH, van den Broek WW, Bruijn JA, Passchier J, Pepplinkhuizen L. Motor
activity and autonomic cardiac functioning in major depressive disorder. J Affect Disord. 2003;
76:23–30. [PubMed: 12943930]
47. Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, Karp B, McCutcheon IE,
Geracioti TD Jr, DeBellis MD, Rice KC, Goldstein DS, Veldhuis JD, Chrousos GP, Oldfield EH,
McCann SM, Gold PW. Pronounced and sustained central hypernoradrenergic function in major
depression with melancholic features: relation to hypercortisolism and corticotropin-releasing
hormone. Proc Natl Acad Sci USA. 2000; 97:325–330. [PubMed: 10618417]
48. Broadley AJ, Frenneaux MP, Moskvina V, Jones CJ, Korszun A. Baroreflex sensitivity is reduced
in depression. Psychosom Med. 2005; 67:648–651. [PubMed: 16046382]
49. Bhagwagar Z, Hafizi S, Cowen PJ3. Increase in concentration of waking salivary cortisol in
recovered patients with depression. Am J Psychiatry. 2003; 160:1890–1891. [PubMed: 14514508]
50. Vreeburg SA, Hoogendijk WJG, van Pelt J, DeRijk RH, Verhagen JCM, van Dyck R, Smit JH,
Zitman FG, Penninx BWJH. Major depressive disorder and hypothalamic-pituitary-adrenal axis
activity results from a large cohort study. Arch Gen Psychiatry. 2009; 66:617–626. [PubMed:
19487626]
51. Kathol RG. Persistent elevation of urinary free cortisol and loss of circannual periodicity in
recovered depressive patients. A trait finding. J Affect Disord. 1985; 8:137–145. [PubMed:
3157722]
52. Young EA, Aggen SH, Prescott CA, Kendler KS. Similarity in saliva cortisol measures in
monozygotic twins and the influence of past major depression. Biol Psychiatry. 2000; 48:70–74.
[PubMed: 10913510]
53. Lok A, Mocking RJT, Ruhe´ HG, Visser I, Koeter MWJ, Assies J, Bockting CLH, Olff M, Schene
AH. Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent
depression. Psychoneuroendocrinology. 2012; 37:892–902. [PubMed: 22094110]
54. Bagley SL, Weaver TL, Buchanan TW. Sex differences in physiological and affective responses to
stress in remitted depression. Physiol Behav. 2011; 104:180–186. [PubMed: 21396947]
55. Girdler SS, Lindgren M, Porcu P, Rubinow DR, Johnson JL, Morrow AL. A history of depression
in women is associated with an altered GABAergic neuroactive steroid profile.
Psychoneuroendocrinology. 2012; 37:543–553. [PubMed: 21890277]
Klatzkin et al. Page 13













56. Ahrens T, Deuschle M, Krumm B, van der Pompe G, den Boer JA, Lederbogen F. Pituitary-
adrenal and sympathetic nervous system responses to stress in women remitted from recurrent
major depression. Psychosom Med. 2008; 70:461–467. [PubMed: 18378864]
57. Morris MC, Rao U, Garber J. Cortisol responses to psychosocial stress predict depression
trajectories: Social-evaluative threat and prior depressive episodes as moderators. J Affect Disord.
2012; 143:223–230. [PubMed: 22858210]
58. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and
validity. Arch Womens Ment Health. 2006; 9:41–49. [PubMed: 16172836]
59. Rubinow DR, Roy-Byrne PP, Hoban MC, Gold PW, Post RM. Prospective assessment of
menstrually related mood disorders. Am J Psychiatry. 1984; 141:684–686. [PubMed: 6538762]
60. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R,
Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and
validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-0. J Clin
Psychiatry. 1998; 59:22–33. [PubMed: 9881538]
61. Stoney CM, Owens JF, Matthews KA, Davis MC, Caggiula A. Influences of the normal menstrual
cycle on physiologic functioning during behavioral stress. Psychophysiology. 1998; 27:125–135.
[PubMed: 2247544]
62. Weidner G, Helmig L. Cardiovascular stress reactivity and mood during the menstrual cycle.
Women Health. 1999; 16:5–21. [PubMed: 2267809]
63. Fleischman DS, Bunevicius A, Leserman J, Girdler SS. Menstrually related mood disorders and a
history of abuse: moderators of pain sensitivity. Health Psychol. 2013 Mar 25. (Epub ahead of
print).
64. Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test'--a tool for investigating
psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993; 28:76–81.
[PubMed: 8255414]
65. Kirschbaum C, Klauer T, Filipp SH, Hellhammer DH. Sex-specific effects of social support on
cortisol and participantive responses to acute psychological stress. Psychosom Med. 1995a; 57:23–
31. [PubMed: 7732155]
66. Kirschbaum C, Prussner JC, Stone AA, Federenko I, Gaab J, Lintz D, Schommer N, Hellhammer
DH. Persistent high cortisol responses to repeated psychological stress in a subpopulation of
healthy men. Psychosom Med. 1995b; 57:468–474. [PubMed: 8552738]
67. Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept
Mot Skills. 1977; 44:367–373. [PubMed: 866038]
68. Dimsdale JE, Ziegler MG. What do plasma and urinary measures of catecholamines tell us about
human response to stressors? Circulation. 1991; 83:36–42.
69. Sherwood A, Allen MT, Fahrenberg J, Kelsey RM, Lovallo WR, van Doornen LJP.
Methodological guidelines for impedance cardiography. Psychophysiology. 1990; 27:1–23.
[PubMed: 2187214]
70. Kubicek WG, Krnegis JN, Patterson RP, Witsoe DA, Mattson RH. Development an evaluation of
impedance cardiac output system. Aerospace Medicine. 1996; 37:1208–1212. [PubMed: 5339656]
71. Blake F, Salkovskis P, Gath D, Day A, Garrod A. Cognitive therapy for premenstrual syndrome: a
controlled trial. J Psychosom Res. 1998; 45:307–318. [PubMed: 9794277]
72. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects
of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl J Med.
1998; 338:209–216. [PubMed: 9435325]
73. Foster PS, Goldie RG, Patterson JW. Effect of steroids on b-adrenoceptor-mediated relaxation of
pig bronchus. Br J Pharmacol. 1983; 78:441–445. [PubMed: 6299446]
74. Heal DJ, Bristow LJ, DeSouza RJ, Bloomfield JG, Hurst EM, Elliott JM. The influence of
injection of estradiol to female rats on changes in a2- and b-adrenoceptor function induced by
repeated administration of desipramine or electroconvulsive shock. Neuropharmacology,. 1998;
27:1151–1159. [PubMed: 2849729]
75. Maggi A, Zucchi I, Perez J. Progesterone in rat brain: modulation of b-adrenergic receptor activity.
Pharmacolog Res Commun. 1985; 17:283–291.
Klatzkin et al. Page 14













76. Wheeldon NM, Newnham DM, Coutie WJ, Peters JA, McDevitt DG, Lipworth BJ. Influence of
sex-steroid hormones on the regulation of lymphocyte beta 2-adrenoceptors during the menstrual
cycle. Br J Clin Pharmacol. 1994; 37:583–588. [PubMed: 7917778]
77. Gurguis GN, Yonkers KA, Blakeley JE, Phan SP, Williams A, Rush AJ. Adrenergic receptors in
premenstrual dysphoric disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling,
phase of menstrual cycle and prediction of luteal phase symptom severity. Psychiatry Res. 1998;
79:31–42. [PubMed: 9676824]
78. Phillips AC, Hunt K, Der G, Carroll D. Blunted cardiac reactions to acute psychological stress
predict symptoms of depression five years later: evidence from a large community study.
Psychophysiology. 2011; 48:142–148. [PubMed: 20536905]
79. Girdler SS, Leserman J, Bunevicius R, Klatzkin R, Pedersen CA, Light KC. Persistent alterations
in biological profiles in women with abuse histories: influence of premenstrual dysphoric disorder.
Health Psychol. 2007; 26:201–213. [PubMed: 17385972]
80. McEwen BS. Stress, adaptation, and disease. Allostasis and allostatic load. Ann NY Acad Sci.
1998; 1:33–44. [PubMed: 9629234]
81. Siever LJ, Davis KL. Overview: toward a dysregulation hypothesis of depression. Am J
Psychiatry. 1985; 142:1017–1031. [PubMed: 2862799]
82. Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on
health and cognition. Neurosci Biobehav Rev. 2010; 35:2–16. [PubMed: 19822172]
83. Robinson MS, Alloy LB. Negative cognitive styles and stress-reactive rumination interact to
predict depression: a prospective study. Cognit Ther Res. 2003; 27:275–292.
84. Alloy LB, Abramson LY, Whitehouse WG, Hogan ME, Panzarella C, Rose DT. Prospective
incidence of first onsets and recurrences of depression in individuals at high and low cognitive risk
for depression. J Abnorm Psychol. 2006; 115:145–156. [PubMed: 16492105]
85. Mechlin MB, Maixner W, Light KC, Fisher JM, Girdler SS. African Americans show alterations in
endogenous pain regulatory mechanisms and reduced pain tolerance to experimental pain
procedures. Psychosom Med. 2005; 67:948–956. [PubMed: 16314600]
Klatzkin et al. Page 15














Mean (±SEM) daily mood ratings core symptom categories as a function of MRMD and
depression history status.
Dep = Depression; Ang/Irr = Anger/Irritability; Anx = Anxiety; Impair = Impairment
Prior Dep = A history of major depressive disorder (n = 45) or dysthymia (n = 1).
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Mean (±SEM) change in heart rate (HR) from baseline to speech and math stress as a
function of MRMD and depression history status.
*MRMD < non-MRMD, p < .01
Prior Dep = A history of major depressive disorder (n = 45) or dysthymia (n = 1).
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Mean (±SEM) change in cardiac index (CI) from baseline to speech and math stress as a
function of MRMD and depression history status
*MRMD < non-MRMD, p < .01
Prior Dep = A history of major depressive disorder (n = 45) or dysthymia (n = 1).
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Mean (±SEM) change in diastolic blood pressure (DBP) from baseline to speech and math
stress as a function of MRMD and depression history status.
+MRMD × History of depression interaction, p = .09; MRMD < non-MRMD only in no
prior depression, p < .01
Prior Dep = A history of major depressive disorder (n = 45) or dysthymia (n = 1).
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Mean (±SEM) change in norepinephrine (NE) from baseline to speech and math stress as a
function of MRMD and depression history status.
+MRMD × History of depression interaction, p < .05; MRMD < non-MRMD only in no
prior depression, p < .01
Prior Dep = A history of major depressive disorder (n = 45) or dysthymia (n = 1).
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Table I














Age (years) 34.4 (± 1.24) 34.0 (± 1.97) 33.1 (± 1.27) 35.3 (± 1.52)
Body Mass Index 24.7 (± 0.86) 27.2 (± 1.61) 27.7 (± 0.96) 26.2 (± 1.34)
Beck Depression InventoryA 1.86 (± 0.36) 3.14 (± 0.76) 7.51 (± 1.15) 7.57 (± 1.23)
State AnxietyA 27.4 (± 1.17) 28.9 (± 1.97) 31.5 (± 1.33) 33.3 (± 1.66)
Months in remission from depression NA 66.8 (± 9.70) NA 106.9 (± 20.0)
No. (%) Minority Race 21 (49%) 5 (25%) 13 (35%) 9 (35%)
No. (%) History of anxiety disordersB 7 (16%) 10 (50%) 8 (22%) 14 (54%)
No. (%) History of substance abuseB 2 (5%) 6 (30%) 3 (11%) 8 (31%)
No. (%) History of suicidalityB 1 (2%) 7 (35%) 4 (11%) 11 (42%)
No. (%) History of eating disorders 1 (2%) 0 (0%) 1 (3%) 4 (15%)
A
MRMD > non-MRMD; p ≤ .01
B
Histories of depression > no histories of depression; ps < .05
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Table II
Mean (±SEM) baseline cardiovascular and plasma norepinephrine levels at rest and, for measures with non-













Systolic Blood Pressure (mmHg) 115.5 (± 1.96) 111.0(± 2.0) C 111.6 (± 2.01) E 113.1 (± 2.62)
Diastolic Blood Pressure (mmHg) 68.9 (± 1.35) 67.4 (± 2.17) C 69.3 (± 1.29) E 67.6 (± 1.90)
Heart Rate (bpm) 66.7 (± 1.64) 65.7 (± 2.99) 64.6 (± 1.62) 67.5 (± 1.60)
Cardiac Index (L/min/m2) 3.7 (± 0.17) 3.3 (± 0.19) B 3.5 (± 0.15) 3.7 (± 0.18)
Total Peripheral Resistance Index (dynes*sec/cm5/
m2)
2070.7 (± 156.8) 3867.5 (± 1887.5) C 2183.6 (± 149.8) E 1972.3 (± 151.0)
Stroke Volume Index (mL/beat/m2) 57.1 (± 3.11) 50.3 (± 4.34) 55.3 (± 4.14) 55.1 (± 3.17)
Norepinephrine (pg/mL) 354.6 (± 17.7) 350.2 (± 29.5) B 325.2 (± 23.6) E 332.7 (± 38.7) F
Delta Speech Systolic Blood Pressure (mmHg) 24.89 (± 1.75) 22.23 (± 3.10) D 22.13 (± 1.88) E 21.86 (± 2.18)
Delta Math Systolic Blood Pressure (mmHg) 14.84 (± 1.36) 13.5 (± 2.4) C 10.73 (± 1.44) E 12.6 (± 1.69)
Delta Speech Total Peripheral Resistance Index
(dynes*sec/cm5/m2)
−193.8 (± 48.8) −218.5 (± 79.3) D −91.0 (± 53.4) E −99.0 (± 82.4)
Delta Math Total Peripheral Resistance Index
(dynes*sec/cm5/m2)
−110.1 (± 37.4) A −175.9 (± 66.3) C −62.3 (± 46.6) E −117.8 (± 47.6)
Delta Speech Stroke Volume Index (mL/beat/m2) 1.07 (± 1.38) −0.52 (± 2.12) B −0.17 (± 1.36) −0.096 (± 1.27)
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